Akeri Mitsuda

741 total citations
8 papers, 257 citations indexed

About

Akeri Mitsuda is a scholar working on Hepatology, Surgery and Epidemiology. According to data from OpenAlex, Akeri Mitsuda has authored 8 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hepatology, 4 papers in Surgery and 4 papers in Epidemiology. Recurrent topics in Akeri Mitsuda's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Liver Disease Diagnosis and Treatment (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Akeri Mitsuda is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Liver Disease Diagnosis and Treatment (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Akeri Mitsuda collaborates with scholars based in Japan and Greece. Akeri Mitsuda's co-authors include Takeaki Suou, Yoshikazu Murawaki, Hironaka Kawasaki, Masahiko Koda, Yutaka Horie, Shiro Ikawa, Kenji Oyama, Hironaka Kawasaki, Kinya Okamoto and Kenji Ohyama and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Hepatology.

In The Last Decade

Akeri Mitsuda

7 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Akeri Mitsuda Japan	5	226	140	44	36	30	8	257
Yabing Guo China	8	179 0.8×	114 0.8×	43 1.0×	27 0.8×	36 1.2×	15	270
V. Ozenne France	3	174 0.8×	125 0.9×	22 0.5×	12 0.3×	22 0.7×	4	194
Jiali Chen China	9	89 0.4×	51 0.4×	29 0.7×	62 1.7×	22 0.7×	10	205
Leida Zhang China	5	107 0.5×	53 0.4×	39 0.9×	31 0.9×	39 1.3×	11	164
Ningyuan Wen China	7	110 0.5×	50 0.4×	59 1.3×	63 1.8×	14 0.5×	22	241
G Benzi Italy	4	318 1.4×	249 1.8×	71 1.6×	18 0.5×	8 0.3×	8	355
Wen‐Bin Ding China	6	67 0.3×	77 0.6×	28 0.6×	25 0.7×	28 0.9×	11	199
Jasmine J. Wang United States	6	87 0.4×	80 0.6×	49 1.1×	35 1.0×	12 0.4×	9	209
Marie Pierre Galais France	4	92 0.4×	49 0.3×	68 1.5×	34 0.9×	17 0.6×	4	193
Katsumi Terashita Japan	7	77 0.3×	39 0.3×	25 0.6×	23 0.6×	32 1.1×	8	189

Countries citing papers authored by Akeri Mitsuda

Since Specialization

Citations

This map shows the geographic impact of Akeri Mitsuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akeri Mitsuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akeri Mitsuda more than expected).

Fields of papers citing papers by Akeri Mitsuda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akeri Mitsuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akeri Mitsuda. The network helps show where Akeri Mitsuda may publish in the future.

Co-authorship network of co-authors of Akeri Mitsuda

This figure shows the co-authorship network connecting the top 25 collaborators of Akeri Mitsuda. A scholar is included among the top collaborators of Akeri Mitsuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akeri Mitsuda. Akeri Mitsuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Fujii, Hideki, Hiroyuki Kimura, Chitomi Hasebe, et al.. (2022). Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. JGH Open. 6(5). 344–352. 2 indexed citations

2.

Tsuchiya, Kaoru, Masayuki Kurosaki, Hiroyuki Marusawa, et al.. (2019). The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan.. Journal of Clinical Oncology. 37(15_suppl). e15629–e15629. 3 indexed citations

3.

Horie, Satoshi, et al.. (2013). [A case of inoperable advanced bile duct cancer treated effectively with combined chemotherapy of gemcitabine and S-1].. PubMed. 40(2). 259–62.

4.

Koda, Masahiko, Yoshikazu Murawaki, Akeri Mitsuda, et al.. (2001). Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma. Cancer. 92(6). 1516–1524. 112 indexed citations

5.

Mitsuda, Akeri, et al.. (2000). Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C. Journal of Hepatology. 32(4). 666–672. 25 indexed citations

6.

Koda, Masahiko, Yoshikazu Murawaki, Akeri Mitsuda, et al.. (2000). Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer. 88(3). 529–537. 8 indexed citations

7.

Murawaki, Yoshikazu, Akeri Mitsuda, Kenji Ohyama, et al.. (2000). Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer. 88(3). 529–537. 100 indexed citations

8.

Okano, Jun‐ichi, et al.. (1996). Rupture of Metastatic Nodule on the Peritoneal Surface Secondary to Hepatocellular Carcinoma.. Internal Medicine. 35(10). 783–784. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact